Macrophage Cell Therapy Completes Dosing in End-Stage Liver Disease Trial
Resolution Therapeutics finishes enrolling all 15 patients in EMERALD, testing a regenerative macrophage therapy that may help cirrhotic livers repair themselves.
Summary
Resolution Therapeutics has completed dosing all 15 patients in the EMERALD Phase I/II trial, testing RTX001, an engineered macrophage cell therapy for end-stage liver disease. The therapy adds IL-10 and MMP-9 to macrophages to boost anti-inflammatory and anti-fibrotic effects, aiming to restart the liver's own repair process rather than replace the organ. Given as a simple outpatient IV infusion in under 10 minutes with no pre-conditioning required, RTX001 is designed to be far more accessible than transplantation. Over 500,000 Americans live with end-stage liver disease, facing grim survival odds after decompensation events. Interim trial results are expected in late 2026, offering the first real-world human data on whether regenerative macrophage therapy can meaningfully alter the course of cirrhosis.
Detailed Summary
End-stage liver disease is a condition where organ failure outpaces medicine's ability to intervene. Liver transplantation remains the only proven reversal, but donor scarcity, surgical complexity, and geographic access leave the majority of patients managing symptoms while their prognosis deteriorates. Resolution Therapeutics, a University of Edinburgh spinout, is pursuing a different path: engineering the body's own immune cells to restart the liver's dormant repair machinery.
The company announced on September 11 that it has dosed the final patient in EMERALD, its Phase I/II trial of RTX001 across hepatology centers in the UK and Spain. Fifteen patients with end-stage liver disease and a history of decompensated cirrhosis have now received the therapy. RTX001 is a Regenerative Macrophage Therapy — macrophages engineered with IL-10, an anti-inflammatory cytokine, and MMP-9, a matrix metalloproteinase that helps break down fibrotic scar tissue. Together, these modifications are designed to give immune cells the tools to reduce inflammation and dissolve the scarring that prevents liver regeneration.
The delivery logistics are notably simple compared to other advanced cell therapies. RTX001 is administered via peripheral IV as an outpatient procedure in under 10 minutes, with no pre-conditioning, bridging therapy, or lymphodepletion required. Manufacturing costs have already been cut by 40%, which is significant for eventual scalability beyond specialist centers.
The stakes are substantial. More than 500,000 Americans currently live with end-stage liver disease, a number projected to reach 600,000 by 2040. After a first decompensation event, 37% of patients die within two years and only 5% receive a transplant. Median survival drops to roughly nine months after a second decompensation.
Interim data from EMERALD are expected in the fourth quarter of 2026. As a first-in-human, single-arm, open-label study, EMERALD is primarily a safety and feasibility read — but it represents the earliest real-world test of whether macrophage-driven organ regeneration can become a clinical reality.
Key Findings
- All 15 patients in the EMERALD Phase I/II trial have been dosed with macrophage therapy RTX001 for end-stage liver disease.
- RTX001 engineers macrophages with IL-10 and MMP-9 to enhance anti-inflammatory and anti-fibrotic liver repair signaling.
- The therapy is delivered as an outpatient IV infusion under 10 minutes with no pre-conditioning or lymphodepletion required.
- Manufacturing cost of goods has been reduced by 40%, improving prospects for broader patient access at scale.
- Interim safety and efficacy data are expected in Q4 2026, providing first human evidence for regenerative macrophage therapy.
Methodology
This is a news report summarizing a clinical milestone announcement from Resolution Therapeutics, not a peer-reviewed research publication. The source, Longevity.Technology, is a credible longevity-focused outlet; the underlying trial is a registered Phase I/II human study. No primary data or peer-reviewed paper is yet available; interim results are pending Q4 2026.
Study Limitations
EMERALD is a first-in-human, single-arm, open-label Phase I/II trial with only 15 patients, so it is powered primarily for safety, not efficacy. No control group exists, limiting causal interpretation of any clinical improvements. Full interim data have not yet been released, and this article is based on a company announcement rather than peer-reviewed findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: